Skip to main navigation Skip to search Skip to main content

Mini-Review on the efficacy and safety of pitavastatin: 'The novel seventh statin gaining momentum'

Research output: Contribution to journal › Review article › peer-review

10 Scopus citations

Abstract

Background: Recently, a plethora of events have affected the statin arena such as muscle-induced myalgia, myopathy, myositis, rare rhabdomyolysis, and new-onset diabetes. The latest statin pitavastatin has emerged with descent stamina (optimum efficacy and improved safety). Objective: The objective of the current review is to explore the pros and cons of pitavastatin as a novel second-generation statin in terms of efficacy and safety that delineate its clinical utility. Methods: The review was conducted via EBSCO hosted Medline search (AL Ain University, UAE subscription) for relevant English written literature articles containing 'pitavastatin' as the primary search term 'pitavastatin and safety;' 'pitavastatin and efficacy' and 'pitavastatin and safety and randomized clinical trials;' and 'pitavastatin and efficacy and randomized clinical trials.' Results: The number of articles containing the word 'pitavastatin' as the primary search term used was (n = 901). The next retrieves MeSH term was 'pitavastatin and safety' (n = 99) and then 'pitavastatin and efficacy' (n = 132). Furthermore, narrowing down the search by adding study design terms revealed: 'pitavastatin and safety and randomized clinical trials,' (n = 10) and 'pitavastatin and efficacy and randomized clinical trials' (n = 13). Combining the two main searches (safety and efficacy) has yielded 23 items, of which 15 articles were satisfying the current mini-review criteria. The prominent efficacy of pitavastatin was depicted by the increase in high-dense lipoprotein cholesterol and a decrease in low-dense lipoprotein cholesterol as illustrated by the clinical trials in the results and discussions section. The safety was enlightened with a very low propensity to cause new-onset diabetes and a low tendency for statin-induced muscular adverse events. Conclusion: Pitavastatin might be suitable for patients with the acute coronary syndrome (ACS), metabolic syndrome, and patients with diabetes. We highly recommend rational individualization for the selection of statin, especially in patients with diabetes and/or with ACS.

Original languageEnglish
Pages (from-to)72-80
Number of pages9
JournalJournal of Pharmacy and Bioallied Sciences
Volume14
Issue number2
DOIs
StatePublished - 1 Apr 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Keywords

  • Pitavastatin and efficacy and randomized clinical trials
  • pitavastatin
  • pitavastatin and efficacy
  • pitavastatin and safety
  • pitavastatin and safety and randomized clinical trials

Fingerprint

Dive into the research topics of 'Mini-Review on the efficacy and safety of pitavastatin: 'The novel seventh statin gaining momentum''. Together they form a unique fingerprint.

Cite this